Related Experiment Videos
[HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]
1Department of Internal Medicine, Tsukuba Memorial Hospital.
Insights
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors effectively lower cholesterol and reduce coronary events. These statins also offer direct anti-atherosclerotic benefits, improving endothelial function and inhibiting plaque development.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Biochemistry
Context:
- Elevated serum cholesterol is a major risk factor for coronary events.
- HMG-CoA reductase inhibitors (statins) are widely used for cholesterol normalization.
- Several statins are clinically available, with more under development.
Purpose:
- To review the established and emerging roles of HMG-CoA reductase inhibitors in cardiovascular disease prevention.
- To highlight the direct anti-atherosclerotic effects of statins beyond lipid-lowering.
Summary:
- Clinical trials confirm statins reduce coronary events by normalizing cholesterol.
- Statins exhibit direct anti-atherosclerotic effects, including improved endothelial function, nitric oxide synthase activity, and reduced platelet aggregation.
- Further demonstrated effects include inhibition of monocyte chemotaxis, smooth muscle cell proliferation, immunosuppression, and induction of apoptosis.
Impact:
- HMG-CoA reductase inhibitors offer significant benefits in reducing hypercholesterolemia and cardiovascular events.
- Their pleiotropic effects suggest broader therapeutic potential in managing atherosclerosis.
- These findings underscore the multifaceted role of statins in cardiovascular health.
Abstract:
Several clinical prevention trials have firmly established that normalization of elevated serum cholesterol levels by 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitors reduces the incidence of coronary events. Four HMG-CoA reductase inhibitors are now available for clinical use in Japan, and two others, under development, are expected to have strong lipid-lowing effects including triglycerides. Indeed, HMG-CoA reductase inhibitors exert direct anti-atherosclerotic effects, independently of their hypocholesterolemic properties. Recently many putative anti-atherogenic effects have been demonstrated, such as improvement in endothelial function, up-regulation of endothelial nitric oxide synthase activity, reduction of platelet thrombus formation, inhibition of monocyte chemotaxis or smooth muscle cell proliferation, and immunosuppressive effect. Moreover, HMG-CoA reductase inhibitors have shown the induction of cell death in vitro, by a pathway involving apoptosis. In conclusion, HMG-CoA reductase inhibitors may play more important roles, in addition to their well established efficacy and cost effectiveness in reducing hypercholesterolemia.